SCHEMBL4021202

SCHEMBL4021202

Nc1ccc(-c2cccc(F)n2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.48
MAP4K4 O95819 1/20 0.47
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
PIK3CD O00329 2/20 0.43
ALOX5AP P20292 3/20 0.42
FEN1 P39748 4/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
ASIC3 Q9UHC3 1/20 0.40
FYN P06241 3/20 0.39
PARP1 P09874 1/20 0.38
DHODH Q02127 1/20 0.38
CTSD P07339 1/20 0.38
BACE1 P56817 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27040352 0.81 ALOX5AP (0.50) MAPTMAP4K4PIK3CDALOX5APFEN1
SCHEMBL13745864 0.79 MAPT (0.48) MAPTNPC1RAB9AALOX5APTDO2
SCHEMBL16835922 0.79 CYP2A6 (0.54) MAP4K4MEN1NPC1RAB9AKMT2A
SCHEMBL29457509 0.79 CYP2A6 (0.54) MAP4K4MEN1NPC1RAB9AKMT2A
SCHEMBL20390897 0.79 ASIC3 (0.53) MAPTALOX5APASIC3DHODH
SCHEMBL27040841 0.77 KMT2A (0.48) MAPTMEN1NPC1RAB9AKMT2A
SCHEMBL13728687 0.75 MAPT (0.45) MAPTALOX5APCTSDBACE1
SCHEMBL4019276 0.72 PIK3CD (0.57) MAP4K4PIK3CDALOX5APFEN1MKNK1
SCHEMBL7009235 0.72 ALDH1A1 (0.46) MAPTMEN1NPC1RAB9AKMT2A
SCHEMBL5012773 0.72 MAP4K4 (0.41) MAPTMAP4K4MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists NPY4R, NPY1R, NPY5R MAPT 4668/4885MAP4K4 2887/4885MEN1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.